Latest & greatest articles for mirtazapine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on mirtazapine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on mirtazapine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for mirtazapine

21. Bupropion, mirtazapine, and reboxetine in the treatment of depression; version 1.0

Bupropion, mirtazapine, and reboxetine in the treatment of depression; version 1.0 Executive Summary IQWiG Reports – Commission No. A05-20C Bupropion, mirtazapine, and reboxetine in the treatment of depression 1 1 Translation of the executive summary of the final report “Bupropion, Mirtazapin und Reboxetin bei der Behandlung der Depression” (Version 1.0; Status: 09.11.2009). Please note that this translation is provided as a service by IQWiG to English-language readers. However, solely (...) the German original text is absolutely authoritative and legally binding. Executive summary of final report A05-20C Bupropion, mirtazapine, and reboxetine in depression Version 1.0 09.11.2009 Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Bupropion, mirtazapine, and reboxetine in the treatment of depression Contracting agency: Federal Joint Committee Commission awarded on: 22.02.2005 Internal Commission No.: A05-20C Publisher’s address: Institute for Quality

Institute for Quality and Efficiency in Healthcare (IQWiG)2009

22. Mirtazapine and nortriptyline similarly effective third-line treatments for depression

Mirtazapine and nortriptyline similarly effective third-line treatments for depression Mirtazapine and nortriptyline similarly effective third-line treatments for depression | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword (...) Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Mirtazapine and nortriptyline similarly effective third-line treatments for depression Article Text Therapeutics Mirtazapine and nortriptyline similarly effective third-line treatments for depression Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish to reuse any or all

Evidence-Based Mental Health2008

23. Mirtazapine reduces social anxiety and improves quality of life in women with social phobia

Mirtazapine reduces social anxiety and improves quality of life in women with social phobia Mirtazapine reduces social anxiety and improves quality of life in women with social phobia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Mirtazapine reduces social anxiety and improves quality of life in women with social phobia Article Text Therapeutics Mirtazapine reduces social anxiety and improves quality of life in women with social phobia Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish

Evidence-Based Mental Health2007

24. Prophylactic mirtazapine may help to prevent post-stroke depression in people with good cognitive function

Prophylactic mirtazapine may help to prevent post-stroke depression in people with good cognitive function Prophylactic mirtazapine may help to prevent post-stroke depression in people with good cognitive function | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Prophylactic mirtazapine may help to prevent post-stroke depression in people with good cognitive function Article Text Therapeutics Prophylactic mirtazapine may help to prevent post-stroke depression in people with good cognitive function Free Jon Erik Ween , MD, MS Statistics from Altmetric.com

Evidence-Based Mental Health2006

25. Mirtazapine plus citalopram has short term but not longer term benefits over citalopram alone for the symptoms of obsessive compulsive disorder

Mirtazapine plus citalopram has short term but not longer term benefits over citalopram alone for the symptoms of obsessive compulsive disorder Mirtazapine plus citalopram has short term but not longer term benefits over citalopram alone for the symptoms of obsessive compulsive disorder | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Mirtazapine plus citalopram has short term but not longer term benefits over citalopram alone for the symptoms of obsessive compulsive disorder Article Text Therapeutics Mirtazapine plus citalopram has short term

Evidence-Based Mental Health2006

26. The cost-effectiveness of mirtazapine versus paroxetine in treating people with depression in primary care

The cost-effectiveness of mirtazapine versus paroxetine in treating people with depression in primary care The cost-effectiveness of mirtazapine versus paroxetine in treating people with depression in primary care The cost-effectiveness of mirtazapine versus paroxetine in treating people with depression in primary care Romeo R, Patel A, Knapp M, Thomas C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of mirtazapine, a noradrenergic and specific serotonergic antidepressant, versus paroxetine, a selective serotonin reuptake inhibitor, for the treatment of patients with depression in primary care. The doses examined were 30 to 45 mg/day mirtazapine and 20 to 30 mg/day paroxetine. Type of intervention Treatment

NHS Economic Evaluation Database.2004

28. New Drugs VII ? Mirtazapine (Remeron®), Salmon-Calcitonin Nasal Spray (Miacalcin®), Gatifloxacin (Tequin®), Moxifloxacin

New Drugs VII ? Mirtazapine (Remeron®), Salmon-Calcitonin Nasal Spray (Miacalcin®), Gatifloxacin (Tequin®), Moxifloxacin [36] New Drugs VI – Rosiglitazone (Avandia®), Tolterodine (Detrol®), Bupropion (Wellbutrin SR®, Zyban®), Doxazosin (Cardura®) | Therapeutics Initiative Independent Healthcare Evidence > > [36] New Drugs VI – Rosiglitazone (Avandia®), Tolterodine (Detrol®), Bupropion (Wellbutrin SR®, Zyban®), Doxazosin (Cardura®) Rosiglitazone (Avandia ® ) Approved indication: To lower blood

Therapeutics Letter2002

29. Cost-effectiveness of mirtazapine relative to fluoxetine in the treatment of moderate and severe depression in France

Cost-effectiveness of mirtazapine relative to fluoxetine in the treatment of moderate and severe depression in France Cost-effectiveness of mirtazapine relative to fluoxetine in the treatment of moderate and severe depression in France Cost-effectiveness of mirtazapine relative to fluoxetine in the treatment of moderate and severe depression in France Brown M C, van Loon J M, Guest J F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The new antidepressant drug mirtazapine was compared with fluoxetine. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with moderate (17-Hamilton-Depression, HAM-D, score of 20 to 25) or severe

NHS Economic Evaluation Database.2000

30. Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK

Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK Borghi J, Guest J F Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients in the UK

NHS Economic Evaluation Database.2000

31. Mirtazapine: a review of its use in major depression

Mirtazapine: a review of its use in major depression Mirtazapine: a review of its use in major depression Mirtazapine: a review of its use in major depression Holm K J, Markham A Authors' objectives To evaluate the use of mirtazapine in patients with major depression. Searching AdiBase, MEDLINE and EMBASE were searched from 1966 with no language restrictions. AdiBase search terms were 'mirtazapine', '6-azamianserin', 'azamianserin', 'mepirzapin', 'Org-3770' and 'depression'. MEDLINE and EMBASE (...) search terms were 'mirtazapine' and 'depression'. Additional references were identified from the reference lists of published articles. Bibliographic information, including contributory unpublished data, was requested from the company developing the drug. Study selection Study designs of evaluations included in the review Double-blind randomised controlled trials (RCTs) and meta-analysis or reviews of RCTs. Most analysis was performed on an intention-to-treat (ITT) basis and included all randomised

DARE.1999

32. Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria

Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria Brown M C J, Nimmerrichter A A, Guest J F Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of mirtazapine, amitriptyline, and fluoxetine in the treatment of moderate and severe depression in Austria. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Austrian people

NHS Economic Evaluation Database.1999

33. Mirtazapine

Mirtazapine Oregon Health & Science University OHSU Digital Commons FDA Drug Approval Documents June 1996 Mirtazapine United States. Food and Drug Administration. Follow this and additional works at: http://digitalcommons.ohsu.edu/fdadrug This Article is brought to you for free and open access by OHSU Digital Commons. It has been accepted for inclusion in FDA Drug Approval Documents by an authorized administrator of OHSU Digital Commons. For more information, please contact champieu@ohsu.edu (...) . Recommended Citation United States. Food and Drug Administration., "Mirtazapine" (1996). FDA Drug Approval Documents. 20. http://digitalcommons.ohsu.edu/fdadrug/20Table 4 Summary of Significance Levels! (2-sided) for Pairwise Comparisons Mirt.azapine vs Placebo in St.udy 003-002 Key Mirtazapine vs Placebo Out.come Variables HAHD-21 Total LOCF OC HA.~D-21 Item 1 LOCF OC MADRS Total CGI 1 2 LOCF· OC Severity LOCF OC Based on Wilcox~n Rank Sum Analys~s p ~ 0.05 t = P .s. 0.10 - == P > 0.10 End of weeks 1-6

FDA Drug Approval Documents (via OHSU)1996